George W Wright
Overview
Explore the profile of George W Wright including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
5126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bolomsky A, Ceribelli M, Scheich S, Rinaldi K, Huang D, Chakraborty P, et al.
Cancer Cell
. 2024 Jun;
42(7):1185-1201.e14.
PMID: 38906156
Multiple myeloma (MM) is an incurable plasma cell malignancy that exploits transcriptional networks driven by IRF4. We employ a multi-omics approach to discover IRF4 vulnerabilities, integrating functional genomics screening, spatial...
2.
Choi J, Ceribelli M, Phelan J, Haupl B, Huang D, Wright G, et al.
Cancer Cell
. 2024 May;
42(5):833-849.e12.
PMID: 38701792
Glucocorticoids have been used for decades to treat lymphomas without an established mechanism of action. Using functional genomic, proteomic, and chemical screens, we discover that glucocorticoids inhibit oncogenic signaling by...
3.
Corcoran S, Phelan J, Choi J, Shevchenko G, Fenner R, Yu X, et al.
Cancer Discov
. 2024 Apr;
14(9):1653-1674.
PMID: 38683128
Polatuzumab vedotin (Pola-V) is an antibody-drug conjugate directed to the CD79B subunit of the B-cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V improves outcomes in diffuse large B-cell lymphoma...
4.
Phelan J, Scheich S, Choi J, Wright G, Haupl B, Young R, et al.
Cancer Cell
. 2024 Jan;
42(2):238-252.e9.
PMID: 38215749
Diffuse large B cell lymphoma (DLBCL) is an aggressive, profoundly heterogeneous cancer, presenting a challenge for precision medicine. Bruton's tyrosine kinase (BTK) inhibitors block B cell receptor (BCR) signaling and...
5.
Scheich S, Chen J, Liu J, Schnutgen F, Enssle J, Ceribelli M, et al.
Cancer Discov
. 2023 May;
13(8):1862-1883.
PMID: 37141112
Significance: DLBCL depends on constitutive BCR activation and signaling. There are currently no therapeutics that target the BCR directly and attenuate its pathologic signaling. Here, we unraveled a therapeutically exploitable,...
6.
Yang Y, Bolomsky A, Oellerich T, Chen P, Ceribelli M, Haupl B, et al.
Nat Commun
. 2022 Oct;
13(1):5830.
PMID: 36192480
No abstract available.
7.
Yang Y, Bolomsky A, Oellerich T, Chen P, Ceribelli M, Haupl B, et al.
Nat Commun
. 2022 Sep;
13(1):5469.
PMID: 36115844
Oncogenic RAS mutations are common in multiple myeloma (MM), an incurable malignancy of plasma cells. However, the mechanisms of pathogenic RAS signaling in this disease remain enigmatic and difficult to...
8.
Shaffer 3rd A, Phelan J, Wang J, Huang D, Wright G, Kasbekar M, et al.
Blood Cancer Discov
. 2021 Nov;
2(6):630-647.
PMID: 34778802
Significance: In diffuse large B-cell lymphoma, we show that primary resistance to BTK inhibitors is due to epigenetic rather than genetic changes that circumvent the BTK blockade. We also observed...
9.
Wilson W, Wright G, Huang D, Hodkinson B, Balasubramanian S, Fan Y, et al.
Cancer Cell
. 2021 Nov;
39(12):1643-1653.e3.
PMID: 34739844
In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene expression subgroup rely upon chronic active B cell receptor signaling for viability, a dependency...
10.
Chiodin G, Allen J, Bryant D, Rock P, Martino E, Valle-Argos B, et al.
Blood
. 2021 Aug;
138(17):1570-1582.
PMID: 34424958
Glycosylation of the surface immunoglobulin (Ig) variable region is a remarkable follicular lymphoma-associated feature rarely seen in normal B cells. Here, we define a subset of diffuse large B-cell lymphomas...